The Appraisal Committee has prepared a Final Appraisal Document (FAD) on Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (managed access review of TA620) ID3788 and submitted it to NICE.

The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors.  The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.

Please note that the appeal period for this appraisal will close at 5pm, Wednesday 21 June 2023

This page was last updated: